Comparison of Anticoagulation Prolongation vs. no Anticoagulation in STEMI Patients After Primary PCI

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2989 participants.

Also called NCT03664180

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 2,989 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03664180
Other papers using this trial's data
  • Postprocedural Anticoagulation After Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction: A Multicenter, Randomized, Double-Blind Trial Circulation, 2024-04-16 DOI, PubMed 38406848

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03664180. Randomized; triple masking; primary purpose treatment. Start 2019-01-11 (actual); primary completion 2022-11-23 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of Anticoagulation Prolongation vs. no Anticoagulation in STEMI Patients After Primary PCI
Acronym
RIGHT
Condition
STEMI - ST Elevation Myocardial Infarction
Intervention (Drug)
Bivalirudin
Intervention (Drug)
Enoxaparin
Intervention (Drug)
Unfractionated heparin
Intervention (Drug)
Bivalirudin placebo
Intervention (Drug)
Enoxaparin placebo syringe
Intervention (Drug)
Unfractionated heparin placebo
Lead sponsor
Beijing Anzhen Hospital (class: other)
Collaborator
Chinese Academy of Medical Sciences, Fuwai Hospital (class: other)
Collaborator
Groupe Hospitalier Pitie-Salpetriere (class: other)

Record details

Record id
cardio:ct-nct03664180
Content hash
2d95261b8b9a92df962b79bb30ac587dc471768d83edd039bef3313a1649e373